Ticarcillin plus clavulanic acid (Timentin) therapy for osteomyelitis

Area of Science:

• Pharmacology
• Infectious Diseases
• Orthopedics

Background:

• Osteomyelitis is a serious bone infection requiring effective antibiotic treatment.
• Timentin (ticarcillin and clavulanic acid) is a novel antibiotic agent.
• Gram-positive and gram-negative bacteria are common causes of osteomyelitis.

Purpose of the Study:

• To evaluate the efficacy and safety of Timentin in treating osteomyelitis.
• To assess the clinical outcomes and microbiological response to Timentin therapy.

Main Methods:

• A study involving 47 patients diagnosed with osteomyelitis via bone biopsy.
• Patients received intravenous Timentin (3.1 g every six hours) for an average of 32 days.
• Repeat bone biopsies and clinical assessments were performed to evaluate treatment outcomes.

Main Results:

• Staphylococcus aureus was the most common isolate (39%), followed by Streptococcus species, Group D Enterococcus, and Pseudomonas aeruginosa.
• Initially, all but one organism were sensitive to Timentin; three resistant organisms emerged during therapy.
• Twenty-seven patients achieved a cure, and 22 showed improvement at follow-up.
• Adverse reactions included mild allergic phenomena, prolonged bleeding times, and transient elevated liver enzymes.

Conclusions:

• Timentin demonstrated significant efficacy in treating bacterial osteomyelitis.
• The antibiotic was effective against a range of gram-positive and gram-negative organisms.
• Timentin presents an exciting therapeutic option for both gram-positive and gram-negative bacterial osteomyelitis.